Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Tesauro, Cinzia ^a   Morozzo della Rocca, Blasco ^a   Ottaviani, Alessio ^a   Coletta, Andrea ^a   Zuccaro, Laura ^a   Arnò, Barbara ^a   D'Annessa, Ilda ^a   Fiorani, Paola ^b   Desideri, Alessandro ^a  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Camptothecin; Drug resistance; Irinotecan; Long range correlation; Molecular dynamics; Mutation; Religation rate; Topoisomerase

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; IRINOTECAN; TOPOISOMERASE IB; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; IN VITRO STUDY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN DOMAIN; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CAMPTOTHECIN; CATALYTIC DOMAIN; DNA CLEAVAGE; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; HCT116 CELLS; HUMANS; KINETICS; MOLECULAR DYNAMICS SIMULATION; MUTATION, MISSENSE; PLASMIDS; PROTEIN STRUCTURE, SECONDARY; SACCHAROMYCES CEREVISIAE; TOPOISOMERASE I INHIBITORS;

EID: 84884806645     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-100     Document Type: Article

References (45)

1. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002, 3:430-440. 10.1038/nrm831, 12042765.
2. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry 2001, 70:369-413. 10.1146/annurev.biochem.70.1.369, 11395412.
3. Stewart L, Ireton GC, Champoux JJ. The domain organization of human topoisomerase I. J Biol Chem 1996, 271:7602-7608. 10.1074/jbc.271.13.7602, 8631794.
4. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998, 279:1504-1513. 10.1126/science.279.5356.1504, 9488644.
5. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998, 279:1534-1541. 10.1126/science.279.5356.1534, 9488652.
6. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009, 109:2894-2902. 10.1021/cr900097c, 2707511, 19476377.
7. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature reviews Cancer 2006, 6:789-802. 10.1038/nrc1977, 16990856.
8. Castelli S, Coletta A, D'Annessa I, Fiorani P, Tesauro C, Desideri A. Interaction between natural compounds and human topoisomerase I. Biol Chem 2012, 393:1327-1340.
9. Leppard JB, Champoux JJ. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 2005, 114:75-85. 10.1007/s00412-005-0345-5, 15830206.
10. Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH. Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 2007, 448:213-217. 10.1038/nature05938, 17589503.
11. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999, 2:307-318. 10.1054/drup.1999.0102, 11504505.
12. Beretta GL, Gatti L, Perego P, Zaffaroni N. Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem 2013, 20:1541-1565. 10.2174/0929867311320120006, 23432590.
13. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 2012, 19:3874-3885. 10.2174/092986712802002590, 22788763.
14. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002, 99:15387-15392. 10.1073/pnas.242259599, 137726, 12426403.
15. Redinbo MR, Stewart L, Champoux JJ, Hol WG. Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J Mol Biol 1999, 292:685-696. 10.1006/jmbi.1999.3065, 10497031.
16. Fiorani P, Bruselles A, Falconi M, Chillemi G, Desideri A, Benedetti P. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J Biol Chem 2003, 278:43268-43275. 10.1074/jbc.M303899200, 12904303.
17. Fiorani P, Tesauro C, Mancini G, Chillemi G, D'Annessa I, Graziani G, Tentori L, Muzi A, Desideri A. Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic acids research 2009, 37:6849-6858. 10.1093/nar/gkp669, 2777420, 19767617.
18. Chillemi G, D'Annessa I, Fiorani P, Losasso C, Benedetti P, Desideri A. Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. Nucleic Acids Res 2008, 36:5645-5651. 10.1093/nar/gkn558, 2553568, 18765473.
19. Fiorani P, Chillemi G, Losasso C, Castelli S, Desideri A. The different cleavage DNA sequence specificity explains the camptothecin resistance of the human topoisomerase I Glu418Lys mutant. Nucl Acids Res 2006, 34:5093-5100. 10.1093/nar/gkl670, 1636438, 16990249.
20. Stewart L, Ireton GC, Champoux JJ. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J Biol Chem 1999, 274:32950-32960. 10.1074/jbc.274.46.32950, 10551862.
21. Chillemi G, Fiorani P, Castelli S, Bruselles A, Benedetti P, Desideri A. Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study. Nucleic acids research 2005, 33:3339-3350. 10.1093/nar/gki642, 1145191, 15944452.
22. Mancini G, D'Annessa I, Coletta A, Sanna N, Chillemi G, Desideri A. Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex. PLoS One 2010, 5:e10934. 10.1371/journal.pone.0010934, 2880615, 20532182.
23. Mancini G, D'Annessa I, Coletta A, Chillemi G, Pommier Y, Cushman M, Desideri A. Binding of an Indenoisoquinoline to the topoisomerase-DNA complex induces reduction of linker mobility and strengthening of protein-DNA interaction. PLoS One 2012, 7:e51354. 10.1371/journal.pone.0051354, 3516564, 23236483.
24. Gongora C, Vezzio-Vie N, Tuduri S, Denis V, Causse A, Auzanneau C, Collod-Beroud G, Coquelle A, Pasero P, Pourquier P, et al. New topoisomerase I mutations are associated with resistance to camptothecin. Mol Cancer 2011, 10:64. 10.1186/1476-4598-10-64, 3120799, 21619602.
25. Kim N, Huang SN, Williams JS, Li YC, Clark AB, Cho JE, Kunkel TA, Pommier Y, Jinks-Robertson S. Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science 2011, 332:1561-1564. 10.1126/science.1205016, 3380281, 21700875.
26. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, Burgin AB. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005, 48:2336-2345. 10.1021/jm049146p, 15801827.
27. Losasso C, Cretaio E, Fiorani P, D'Annessa I, Chillemi G, Benedetti P. A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res 2008, 36:5635-5644. 10.1093/nar/gkn557, 2553582, 18772225.
28. D'Annessa I, Tesauro C, Fiorani P, Chillemi G, Castelli S, Vassallo O, Capranico G, Desideri A. Role of flexibility in protein-DNA-drug recognition: the case of Asp677Gly-Val703Ile topoisomerase mutant hypersensitive to camptothecin. J Amino Acids 2012, 2012:206083. 3270393, 22315664.
29. Arno B, D'Annessa I, Tesauro C, Zuccaro L, Ottaviani A, Knudsen B, Fiorani P, Desideri A. Replacement of the human topoisomerase linker domain with the plasmodial counterpart renders the enzyme camptothecin resistant. PLoS One 2013, 8:e68404. 10.1371/journal.pone.0068404, 3699648, 23844196.
30. Koster DA, Croquette V, Dekker C, Shuman S, Dekker NH. Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature 2005, 434:671-674. 10.1038/nature03395, 15800630.
31. Bjornsti MA, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 1989, 49:6318-6323.
32. Kauh EA, Bjornsti MA. SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proc Natl Acad Sci USA 1995, 92:6299-6303. 10.1073/pnas.92.14.6299, 41505, 7603986.
33. Kaiser C, Michaelis S, Mitchell A. Lithium acetate yeast transformation 1994, 133-134. New York: Cold Spring Harbor Laboratory Press.
34. Image J http://rsbweb.nih.gov/ij.
35. Andersen AH, Gocke E, Bonven BJ, Nielsen OF, Westergaard O. Topoisomerase I has a strong binding preference for a conserved hexadecameric sequence in the promoter region of the rRNA gene from tetrahymena pyriformis. Nucleic Acids Res 1985, 13:1543-1557. 10.1093/nar/13.5.1543, 341095, 2987828.
36. Yang Z, Champoux JJ. Reconstitution of enzymatic activity by the association of the cap and catalytic domains of human topoisomerase I. J Biol Chem 2002, 277:30815-30823. 10.1074/jbc.M205302200, 12077150.
37. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004, 25:1605-1612. 10.1002/jcc.20084, 15264254.
38. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, et al. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem 2003, 24:1999-2012. 10.1002/jcc.10349, 14531054.
39. Sorin EJ, Pande VS. Exploring the helix-coil transition via all-atom equilibrium ensemble simulations. Biophys J 2005, 88:2472-2493. 10.1529/biophysj.104.051938, 1305346, 15665128.
40. Hess B. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008, 4:435-447.
41. Jorgensen WCJ, Madura J, Impey R, Klein M. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983, 79:926-935.
42. TE Cheatham MJ, Fox T, Darden TA, Kollman PA. Molecular-dynamics simulations on solvated biomolecular systems - the particle mesh Ewald method leads to stable trajectories of DNA, Rna, and proteins. J Am Chem Soc 1995, 117:4193-4194.
43. Hess BBH, Berendsen H, Fraaije J. LINCS: a linear constraint solver for molecular simulations. J Comput Chem 1997, 18:1463-1472.
44. Parrinello MRA. Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 1981, 52:7182-7190.
45. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996, 14:33-38. 27-38, 10.1016/0263-7855(96)00018-5, 8744570.